180 reports of this reaction
1.4% of all CARIPRAZINE reports
#19 most reported adverse reaction
EXTRAPYRAMIDAL DISORDER is the #19 most commonly reported adverse reaction for CARIPRAZINE, manufactured by Allergan, Inc.. There are 180 FDA adverse event reports linking CARIPRAZINE to EXTRAPYRAMIDAL DISORDER. This represents approximately 1.4% of all 13,196 adverse event reports for this drug.
Patients taking CARIPRAZINE who experience extrapyramidal disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXTRAPYRAMIDAL DISORDER is a less commonly reported adverse event for CARIPRAZINE, but still significant enough to appear in the safety profile.
In addition to extrapyramidal disorder, the following adverse reactions have been reported for CARIPRAZINE:
The following drugs have also been linked to extrapyramidal disorder in FDA adverse event reports:
EXTRAPYRAMIDAL DISORDER has been reported as an adverse event in 180 FDA reports for CARIPRAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXTRAPYRAMIDAL DISORDER accounts for approximately 1.4% of all adverse event reports for CARIPRAZINE, making it a notable side effect.
If you experience extrapyramidal disorder while taking CARIPRAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.